Researcher profile

Naruki Yoshikawa

Naruki Yoshikawa contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
4topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2026arXiv

NIMO Controller: a self-driving laboratory orchestrator based on the Model Context Protocol

Self-driving laboratories (SDLs) have attracted increasing attention as a means of accelerating scientific discovery; however, developing SDL software remains technically demanding. To improve accessibility, orchestration software frameworks have been proposed to coordinate SDL components. Nevertheless, existing frameworks are primarily designed for human interaction and do not provide standardized interfaces suitable for AI agents. In this work, we propose an SDL software architecture based on the Model Context Protocol (MCP), in which all SDL functionalities are exposed through MCP servers. Following this design principle, we introduce an MCP-based SDL orchestrator, named NIMO Controller. It provides a visual programming interface automatically generated through MCP-based tool discovery, allowing human users to design experimental workflows without writing code. The same MCP backend can also be accessed by AI agents, providing a unified interface for both human users and AI agents. We demonstrate the proposed system through a case study on a color-matching SDL. The results validate the usability of the proposed MCP-based SDL architecture.

preprint2021arXiv

Assigning Confidence to Molecular Property Prediction

Introduction: Computational modeling has rapidly advanced over the last decades, especially to predict molecular properties for chemistry, material science and drug design. Recently, machine learning techniques have emerged as a powerful and cost-effective strategy to learn from existing datasets and perform predictions on unseen molecules. Accordingly, the explosive rise of data-driven techniques raises an important question: What confidence can be assigned to molecular property predictions and what techniques can be used for that purpose? Areas covered: In this work, we discuss popular strategies for predicting molecular properties relevant to drug design, their corresponding uncertainty sources and methods to quantify uncertainty and confidence. First, our considerations for assessing confidence begin with dataset bias and size, data-driven property prediction and feature design. Next, we discuss property simulation via molecular docking, and free-energy simulations of binding affinity in detail. Lastly, we investigate how these uncertainties propagate to generative models, as they are usually coupled with property predictors. Expert opinion: Computational techniques are paramount to reduce the prohibitive cost and timing of brute-force experimentation when exploring the enormous chemical space. We believe that assessing uncertainty in property prediction models is essential whenever closed-loop drug design campaigns relying on high-throughput virtual screening are deployed. Accordingly, considering sources of uncertainty leads to better-informed experimental validations, more reliable predictions and to more realistic expectations of the entire workflow. Overall, this increases confidence in the predictions and designs and, ultimately, accelerates drug design.